THLN
Nonapeptide hormone produced by thymic epithelial cells. Reviews describe its involvement in intra- and extrathymic T-cell differentiation.
Regulatory status (as of Sept 2026)
Not FDA-approved.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote3 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Thymulin is a compound studied only in animals and lab experiments so far. Nonapeptide hormone produced by thymic epithelial cells.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Preclinical (animal) |
| Dosing | Published research: No published human dosing detailsNo published human dosing study found; the reviews found describe animal and in vitro work only.Community-reportedCommunity-reported: 1–10 mcg, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a thymus hormone that needs zinc to work and helps immune T cells develop. Zinc-dependent thymic nonapeptide whose activity depends on bound zinc. Described as inducing T-cell differentiation and enhancing T-cell subset functions in normal or partly thymus-deficient recipients (review, Bach 1989).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedCommonly reported doses range from 1 to 10 mcg (subcutaneous injection). This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Thymulin | Unknown | Subcutaneous injection | Preclinical (animal) |
| KPV | No published PK data found | Subcutaneous injection, Oral, Topical | Preclinical (animal) |
| LL-37 | Unknown | Subcutaneous injection | Phase 2 |
| Thymalin | No published PK data found | Intramuscular injection | Approved outside US |
| Thymopoietin II Fragment (TP-1) | Unknown | Subcutaneous injection | Preclinical (animal) |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Immune category. View All Immune Peptides
Anti-Aging
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.